TP53 and B-cell chronic lymphocytic leukemia: The population was broader than in ELEVATE-TN, with all BTKi-naïve relapsed CLL patients enrolled, and was a relatively low-risk patient cohort (median number of prior lines 1, TP53 mutated/17p deletion 23%).